title: [Medication of the month. asenapine (Sycrest].
abstract: Asenapine is a new atypical antipsychotic. Like other atypicals, asenapine acts as an antagonist at both dopamine D2 and serotonin 5-HT2A receptors. The efficacy of asenapine monotherapy in the treatment of bipolar disorder manic episodes in adults has been demonstrated in two similarly designed randomized placebo-controlled flexible-dose trials of 3 weeks' duration, using olanzapine as active reference. Asenapine is associated with a good tolerability profile. In particular, asenapine induces a moderate weight gain, and does not increase serum levels of lipids or fasting glucose.
authors.affiliation: Service de Psychiatrie et de Psychologie Médicale, CHU de Liège, Belgique. wpitchot@chu.ulg.ac.be
authors.forename: W
authors.initials: W
authors.lastname: Pitchot
mesh_terms: D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans
chemical_list: D014150:Antipsychotic Agents; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings; C522667:asenapine